Galecto Grants 312,535 Stock Options to New Employee

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Dec 16 2025

0mins

GLTO+11.62%

Should l Buy GLTO?

Source: Newsfilter

Stock Option Grant: On December 15, 2025, Galecto's Board approved the grant of 312,535 non-qualified stock options to a new employee at an exercise price of $32.00 per share, aimed at attracting talent and enhancing the company's competitive edge.
Incentive Plan: The grant is made under the Company's 2022 Inducement Plan, with options vesting 25% on the first anniversary and 1/48th monthly thereafter, ensuring the employee's continued employment to earn the options.
Talent Attraction: By offering attractive stock options, Galecto aims to draw key talent to support its clinical development in hematological cancer treatments, thereby strengthening its market position in the biotechnology sector.
Future Outlook: Galecto expects to submit an IND application for its lead asset DMR-001 in mid-2026, further advancing its antibody therapeutic pipeline and enhancing the company's innovative capabilities in treating blood cancers.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy GLTO?" and start using high-conviction signals backed by rigorous historical data.

GLTO

$25.26+Infinity%1D

Analyst Views on GLTO

Wall Street analysts forecast GLTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLTO is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 22.630

Low

36.00

Averages

41.00

High

46.00

Current: 22.630

Low

36.00

Averages

41.00

High

46.00

LifeSci Capital

Outperform

initiated

$40

2026-02-02

Reason

LifeSci Capital

Price Target

$40

AI Analysis

2026-02-02

initiated

Outperform

Reason

LifeSci Capital initiated coverage of Galecto with an Outperform rating and $40 price target.

Leerink

Outperform

initiated

$46

2026-01-07

Reason

Leerink

Price Target

$46

2026-01-07

initiated

Outperform

Reason

Leerink initiated coverage of Galecto with an Outperform rating and $46 price target. In a reverse merger, Galecto acquired Damora Therapeutics to advance a pipeline targeting hematological cancers, including mutant calreticulin-(mCALR)-driven myeloproliferative neoplasms, important mutations driving pathology in essential thrombocythemia and myelofibrosis. The firm thinks lead asset DMR-001 has the potential to be a best-in-class agent for mCALR-driven MPNs, including patients with Type 1 and Type 2 mCALR mutations. Importantly, central to Leerink's investment thesis is the disease-modifying mechanism of action for mCALR agents, which could meaningfully expand the market. It forecasts DMR-001 could generate peak sales of $3.3B in MF and $3B in ET, which represents $21/share and $19/share in the firm's valuation model, respectively.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GLTO

Unlock Now

About GLTO

Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Galecto Appoints New Executives to Advance DMR-001 Clinical Trials

Jan 06 2026Globenewswire

Executive Appointments: Galecto has appointed Sherwin Sattarzadeh as COO and Becker Hewes as CMO, both from Blueprint Medicines, leveraging their 20+ years of drug development experience to drive DMR-001 into clinical trials.
Clinical Advancement: DMR-001, a monoclonal antibody targeting mutant calreticulin, is on track for IND submission in mid-2026, with plans for first-in-human dosing via subcutaneous administration, marking a significant step in blood cancer treatment.
Financial Position: The company's cash balance, including $285 million raised in a PIPE in November 2025, provides a financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 expected in 2027.
Incentive Plan: The appointments of Sattarzadeh and Hewes come with stock incentive grants of 190,376 and 264,629 restricted stock units respectively, reflecting the company's commitment to its executive team and confidence in future growth.

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%

Dec 26 2025Benzinga

Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.